…MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of potential cancer indications. Terms of the agreement were not disclosed.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”